A Multicenter Study Aiming to Clarify the Prevalence and Clinical Implications of ATTR Cardiac Amyloidosis in Patients with Heart Failure with Preserved/Mid-range Ejection Fractio

Not Applicable

Recruiting

• Conditions: Heart failure; Preserved/Mid-range Ejection Fraction, ATTR Cardiac Amyloidosis; D006333

• Registration Number: JPRN-jRCT1031210714
• Lead Sponsor: Matsue Yuya

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

i)Age >= 70 years old and < 90 years old
ii)Admitted under the diagnosis of heart failure based on Framingham criteria
iii)Left ventricular ejection fraction measured by echocardiography or CMR is >=40%
iv)Maximal left ventricular wall thickness >10 mm by echocardiography or CMR performed within 3 months
v)Those who have obtained written consent for participation in the study

Exclusion Criteria

i)Amyloid has been already proven histologically
ii)Any cardiac surgery or major chest trauma within 4 weeks of index visit
iii)Treatment of heart failure with intravenous drugs
iv)History of myocardial infarction, and history of coronary artery disease needed coronary artery revascularization, including PCI/CABG within 6 months
v)Uncontrolled infection, or active malignancy, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
vi)Received or planned liver transplant or heart transplant

Study & Design

• Study Type: Observational
• Study Design: Not specified